KG&L Capital Management LLC Reduces Stock Holdings in GSK plc (NYSE:GSK)

KG&L Capital Management LLC reduced its position in GSK plc (NYSE:GSK) by 21.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,031 shares of the pharmaceutical company’s stock after selling 3,654 shares during the quarter. KG&L Capital Management LLC’s holdings in GSK were worth $441,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in GSK. AQR Capital Management LLC raised its stake in GSK by 103.4% in the 2nd quarter. AQR Capital Management LLC now owns 26,363 shares of the pharmaceutical company’s stock valued at $1,015,000 after acquiring an additional 13,403 shares during the period. NewEdge Advisors LLC lifted its stake in shares of GSK by 61.9% during the 2nd quarter. NewEdge Advisors LLC now owns 70,048 shares of the pharmaceutical company’s stock valued at $2,697,000 after buying an additional 26,793 shares in the last quarter. Sanctuary Advisors LLC bought a new position in GSK in the 2nd quarter worth approximately $11,181,000. Trust Co. of Toledo NA OH grew its stake in GSK by 6.6% in the 3rd quarter. Trust Co. of Toledo NA OH now owns 32,679 shares of the pharmaceutical company’s stock valued at $1,336,000 after buying an additional 2,015 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in GSK by 167.3% during the 3rd quarter. SG Americas Securities LLC now owns 18,773 shares of the pharmaceutical company’s stock valued at $767,000 after acquiring an additional 11,749 shares during the period. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Down 0.4 %

GSK stock opened at $35.20 on Friday. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The stock has a market cap of $72.96 billion, a price-to-earnings ratio of 22.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.63. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The company’s 50 day moving average is $34.07 and its 200 day moving average is $37.69.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on GSK shares. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Six analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.